Abstract
Limited information is available concerning the use of ganciclovir (GCV) in patients with severe renal impairment. The pharmacokinetics of GCV were studied in a heart transplant recipient requiring hemodialysis. The total body clearance was calculated to be approximately 5% of that previously reported for patients with normal renal function. GCV was removed by hemodialysis; a single 4-h procedure decreased the concentration in plasma by approximately 50%. GCV can be safely administered to patients with renal insufficiency if concentrations in plasma are monitored.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1899-1900 |
| Number of pages | 2 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 32 |
| Issue number | 12 |
| DOIs | |
| State | Published - 1988 |